Krishna Institute of Medical Sciences Ltd (KIMS) — shareholding pattern, promoter holding, financials and share price
About Krishna Institute of Medical Sciences Ltd (KIMS)
Krishna Institute of Medical Sciences Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as KIMS and on the BSE under scrip code 543308. Its ISIN is INE967H01025.
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.
Krishna Institute of Medical Sciences Limited operates an integrated multi‑specialty hospital network delivering tertiary and quaternary care across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala, focusing on complex specialities such as cardiac sciences, organ transplantation, neurosciences and oncology under the KIMS Hospitals brand.
Q3 FY26 marked a record consolidated quarter with total revenue crossing INR 1,003 crore, driven by higher ARPOB and new hospital contributions, but profitability compressed: EBITDA margin fell to 20.4% and PAT declined materially year‑on‑year due to start‑up losses, higher finance cost and depreciation from recent expansions.
Listed peers in Hospital: Aster DM Healthcare Ltd, Narayana Hrudayalaya Ltd, Global Health Ltd, Dr Agarwals Health Care Ltd, Rainbow Childrens Medicare Ltd, Park Medi World Ltd.
Valuation & Returns
10 Jul 2026At ₹813.9 a share on 10 Jul 2026, Krishna Institute of Medical Sciences Ltd (KIMS) was valued at a price-to-earnings ratio of 141.08x against an industry P/E of 61.73x and a price-to-book of 15.99x on a book value of ₹50.9 per share as of Mar 2025. Solomo computes return on equity of 11.33% and return on capital employed of 11.43% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 141.08x
- Industry P/E
- 61.73x
- P/B
- 15.99x
- EPS (TTM)
- ₹5.77
- Book value / share
- ₹50.9
- ROE
- 11.33%
- ROCE
- 11.43%
- ROA
- 4.22%
- Debt / equity
- 1.2x
- Dividend yield
- 0%
- EBITDA margin
- 20.99%
- 52-week range
- ₹575.55 – ₹858.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Krishna Institute of Medical Sciences Ltd (KIMS) reported revenue of ₹3,905 crore, net profit of ₹242 crore and earnings per share of ₹6.03. That compares with revenue of ₹3,035 crore and net profit of ₹415 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,075 crore and net profit ₹33 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,651 | 2,198 | 2,498 | 3,035 | 3,905 |
| Net profit (₹ cr) | 344 | 366 | 336 | 415 | 242 |
| EPS (₹) | 8.32 | 8.41 | 7.75 | 9.61 | 6.03 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 11.87% | 6.58% | 21.49% |
| Profit growth | 20.12% | 2.86% | 23.45% |
| Stock price CAGR | 26% | 28% | 8% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 32.5% of Krishna Institute of Medical Sciences Ltd (KIMS) (down 1.61 pp QoQ), foreign institutional investors (FII) hold 14.74% and domestic institutional investors (DII) hold 34.43%. Promoters have pledged 10.3% of their holding. Market capitalisation was ₹34,184 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2021.
Largest disclosed public shareholders in Jun 2026: Sbi Small Cap Fund 5.17%, Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund 4.5%, Hdfc Small Cap Fund 3.98%, Bollineni Seenaiah Naidu 3.93%, Kotak Small Cap Fund 3.61%, Invesco India Flexi Cap Fun 3.54%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 32.5% | 10.3% | 14.74% | 34.43% | 67.5% |
| Mar 2026 | 34.11% | 10.3% | 14.57% | 32.5% | 65.89% |
| Dec 2025 | 34.11% | 3.7% | 14.33% | 32.71% | 65.89% |
| Sep 2025 | 34.11% | - | 15.03% | 32.12% | 65.89% |
| Jun 2025 | 34.11% | - | 15.54% | 31.66% | 65.89% |
| Mar 2025 | 38.82% | 12% | 15.45% | 31.95% | 61.18% |
| Dec 2024 | 38.82% | 12.1% | 15.68% | 32.05% | 61.18% |
| Sep 2024 | 38.82% | 15.3% | 15.85% | 32.3% | 61.18% |